Bryan Lau

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies
    Bryan Lau
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Epidemiology 20:664-72. 2009
  2. ncbi Evaluating competing adverse and beneficial outcomes using a mixture model
    Bryan Lau
    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Stat Med 27:4313-27. 2008
  3. ncbi Interval and clinical cohort studies: epidemiological issues
    Bryan Lau
    Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, USA
    AIDS Res Hum Retroviruses 23:769-76. 2007
  4. ncbi Competing risk regression models for epidemiologic data
    Bryan Lau
    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Am J Epidemiol 170:244-56. 2009
  5. ncbi Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3
    Bryan Lau
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 44:179-87. 2007
  6. ncbi C-reactive protein is a marker for human immunodeficiency virus disease progression
    Bryan Lau
    Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Arch Intern Med 166:64-70. 2006
  7. ncbi Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    AIDS 17:2035-44. 2003
  8. ncbi Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 39:620-5. 2005
  9. ncbi Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy
    Michael J Mugavero
    Department of Medicine, Division of Infectious Diseases, University of Alabama, Birmingham, AL, USA
    Clin Infect Dis 53:927-35. 2011
  10. ncbi Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival
    Robyn C Neblett
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Womens Health (Larchmt) 20:279-86. 2011

Detail Information

Publications24

  1. ncbi Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies
    Bryan Lau
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Epidemiology 20:664-72. 2009
    ..No studies have evaluated the impact of the frequency of marker measurements for either their predictive value of mortality or how they may influence inference of the effect of therapy initiation in analyses from observational data...
  2. ncbi Evaluating competing adverse and beneficial outcomes using a mixture model
    Bryan Lau
    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Stat Med 27:4313-27. 2008
    ....
  3. ncbi Interval and clinical cohort studies: epidemiological issues
    Bryan Lau
    Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, USA
    AIDS Res Hum Retroviruses 23:769-76. 2007
    ..The interval and clinical cohort designs are distinguished and the advantages and disadvantages inherent in each design are discussed...
  4. ncbi Competing risk regression models for epidemiologic data
    Bryan Lau
    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Am J Epidemiol 170:244-56. 2009
    ..71, 95% confidence interval: 1.37, 2.13 and (sd)RH = 2.01, 95% confidence interval: 1.62, 2.51). Methods for competing risks should be used by epidemiologists, with the choice of method guided by the scientific question...
  5. ncbi Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3
    Bryan Lau
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 44:179-87. 2007
    ..To quantify cause-specific mortality risk attributable to non-AIDS-related and AIDS-related causes before and after the advent of highly active antiretroviral therapy (HAART)...
  6. ncbi C-reactive protein is a marker for human immunodeficiency virus disease progression
    Bryan Lau
    Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Arch Intern Med 166:64-70. 2006
    ..Limited data on acute-phase C-reactive protein (CRP) levels in human immunodeficiency virus (HIV) infection exist...
  7. ncbi Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    AIDS 17:2035-44. 2003
    ..These results suggest that TLC and Hgb might be useful for monitoring disease progression in resource-limited settings...
  8. ncbi Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 39:620-5. 2005
    ..These results support the potential utility of these markers for monitoring HIV-infected people in resource-limited regions, but critical levels and rates of decline of markers for such regions remain to be defined...
  9. ncbi Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy
    Michael J Mugavero
    Department of Medicine, Division of Infectious Diseases, University of Alabama, Birmingham, AL, USA
    Clin Infect Dis 53:927-35. 2011
    ..We evaluated the cumulative effect of exposure to HIV replication on mortality following initiation of combination antiretroviral therapy (ART)...
  10. ncbi Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival
    Robyn C Neblett
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Womens Health (Larchmt) 20:279-86. 2011
    ..We sought to determine factors associated with alcohol use among HIV-infected women engaged in clinical care and if baseline alcohol use was associated with time to combination antiretroviral therapy (cART) and death in this population...
  11. ncbi Methods for the analysis of continuous biomarker assay data with increased sensitivity
    Bryan Lau
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    Epidemiology 15:724-32. 2004
    ....
  12. ncbi Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry
    Bryan Lau
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Stat Med 30:654-65. 2011
    ..An application to the Women's Interagency HIV Study is provided to investigate injection drug use and the time to either the initiation of effective antiretroviral therapy, or clinical disease progression as a competing event...
  13. ncbi HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users
    Megan L Salter
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    Clin Infect Dis 53:1256-64. 2011
    ....
  14. ncbi Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1
    Megan Wind-Rotolo
    Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Infect Dis 199:1301-9. 2009
    ..Although resistant viruses fade to undetectable levels in plasma, they may persist as stably integrated proviruses within the latent reservoir in resting CD4(+) T cells, potentially complicating future treatment...
  15. ncbi Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america
    Alison G Abraham
    Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Suite E7640, Baltimore, MD 21205, USA
    Am J Epidemiol 174:727-35. 2011
    ....
  16. ncbi Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy
    Stephen J Gange
    Department of Epidemiology and Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
    AIDS 17:119-21. 2003
  17. ncbi Virologic and immunologic response to HAART, by age and regimen class
    Keri N Althoff
    Johns Hopkins University, Baltimore, Maryland 21287, USA
    AIDS 24:2469-79. 2010
    ..To determine the impact of age and initial HAART regimen class on virologic and immunologic response within 24 months after initiation...
  18. ncbi Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection
    Geetanjali Chander
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 43:411-7. 2006
    ..We examined the independent effect of alcohol and combined effects of drug and alcohol use on antiretroviral (ART) utilization, adherence, and viral suppression in an urban cohort of HIV-infected individuals...
  19. ncbi Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study
    Bryan Lau
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N, Wolfe Street, Baltimore, Maryland 21205, USA
    AIDS Res Ther 7:25. 2010
    ..We assessed whether routinely collected clinical markers could improve prediction of concurrent HIV RNA levels...
  20. ncbi Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial
    Gregory M Lucas
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Intern Med 152:704-11. 2010
    ..Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings...
  21. ncbi Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening
    Timothy R Sterling
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Infect Dis 204:893-901. 2011
    ..Identifying factors associated with developing tuberculosis after HAART initiation could focus screening efforts...
  22. ncbi Exceeding the limits of liver histology markers
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 1830 E Monument St, Room 455 ID, Baltimore, MD 21287, USA
    J Hepatol 50:36-41. 2009
    ..We characterized the magnitude of the impact of error in the "gold standard" on the observed diagnostic accuracy of surrogate markers...
  23. ncbi Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races
    Gregory M Lucas
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicines, Baltimore, Maryland, USA
    J Infect Dis 197:1548-57. 2008
    ..Little is known about the racial differences in the incidence and progression of HIV-related chronic kidney disease (CKD) that underlie African American-white disparities in HIV-related end-stage renal disease (ESRD)...
  24. ncbi Importance of age of onset in pancreatic cancer kindreds
    Kieran A Brune
    Department of Pathology, Sol Goldman Pancreatic Cancer Research Center at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Natl Cancer Inst 102:119-26. 2010
    ..Young-onset cancer is a hallmark of many familial cancer syndromes, yet the implications of young-onset disease in predicting risk of pancreatic cancer among familial pancreatic cancer (FPC) kindred members remain unclear...